1291P Hypersensitivity reactions (HR) to selpercatinib in RET fusion+ non-small cell lung cancer (NSCLC) patients (pts) following immune checkpoint inhibition (CPI)

Authors :: Victoria Soldatenkova
K. Park
Viola W. Zhu
C. McCoach
L. Potter
D.S.W. Tan
Koichi Goto
Jennifer Kherani
Christian D. Rolfo
E. Olek
Benjamin Besse
S. Farajian
Pablo Lee
Source :: Annals of Oncology. 31:S835-S836
Publication Year :: 2020
Publisher :: Elsevier BV, 2020.

Subjects :: Oncology
business.industry
medicine
Cancer research
non-small cell lung cancer (NSCLC)
Hematology
RET Fusion
medicine.disease
business
Immune checkpoint

Tools